Document:

EX-10.19

 Exhibit 10.19 
 AMENDMENT TO 
 EMPLOYMENT AGREEMENT 

THIS AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is entered into effective as of July 2, 2013, by and
between Alfred P. Spada, Ph.D. (“Employee”) and Conatus Pharmaceuticals Inc., a Delaware corporation (the “Company”). 
 WHEREAS, the Company and Employee are parties to that certain Employment Agreement dated as of December 17, 2008 (the “Agreement”); and 

WHEREAS, the Company and Employee desire to amend the Agreement on the terms and conditions set forth below. 

NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and adequacy of which is
hereby acknowledged, the Company and Employee hereby amend the Agreement as follows: 
 1. For purposes of the Agreement and this
Amendment, the following term shall have the following meaning: 
 “Public Trading Date. “Public Trading
Date” shall mean the first date upon which the Company’s common stock is listed (or approved for listing) upon notice of issuance on any securities exchange or designated (or approved for designation) upon notice of issuance as a
national market security on an interdealer quotation system.” 
 2. The first sentence of Section 4(a) of the
Agreement is hereby amended to read as follows: 
 “The Company shall pay to Employee a base salary of $283,111.86 per year,
payable in accordance with the Company’s usual pay practices (and in any event no less frequently than bi-monthly).” 

3. The second sentence of Section 4(b) of the Agreement is hereby amended to read as follows: 

“Upon full attainment of the aforementioned criteria, as determined by the Board or its designee, the Annual Bonus will be equal to
thirty-five percent (35%) of Employee’s then-current base salary actually paid for such fiscal year.” 
 4.
Section 4(g) of the Agreement is hereby amended to read as follows: 
 “(g) Acceleration of Vesting of Stock
Awards. 
 (i) With respect to Stock Awards granted to Employee prior to the Public Trading Date, the
vesting and/or exercisability of one hundred percent (100%) of such Stock Awards shall be automatically accelerated on the date of a Change of Control. 

 (ii) With respect to Stock Awards granted to Employee on or after the
Public Trading Date, (A) the vesting and/or exercisability of fifty percent (50%) of the then-unvested and outstanding portion of such Stock Awards shall be automatically accelerated on the date of a Change of Control, and (B) the
remaining fifty percent (50%) of the then-unvested and outstanding portion of such Stock Awards shall vest and/or become exercisable on the first to occur of (1) the first anniversary of the Change of Control or (2) the date of
Employee’s termination of employment by the Company without Cause or by Employee for Good Reason. 

(iii) Subject to Section 5(c), if Employee’s employment is terminated by the Company without Cause or by
Employee for Good Reason, the vesting and/or exercisability of each of Employee’s outstanding Stock Awards shall be automatically accelerated on the date of termination as to the number of Stock Awards that would vest over the twelve
(12) month period following the date of termination had Employee remained continuously employed by the Company during such period. 
 (iv) The foregoing provisions are hereby deemed to be a part of each Stock Award and to supersede any less favorable provision in any agreement or plan regarding such Stock Award.” 

5. Section 5(a)(iii) of the Agreement is hereby amended to read as follows: 

“(iii) subject to Sections 5(c), 5(g) and 5(h) and Employee’s continuing compliance with Section 6, for the
period beginning on the date of termination and ending on the date which is twelve (12) full months following the date of termination (or, if earlier, the date on which the applicable continuation period under the Consolidated Omnibus Budget
Reconciliation Act of 1985, as amended (“COBRA”) expires) (the “COBRA Coverage Period”), the Company shall pay for and provide to Employee and his or her eligible dependents who were covered under the Company’s
health insurance plans immediately prior to the date of termination with healthcare insurance benefits substantially similar to those provided to Employee and his or her eligible dependents immediately prior to the date of termination. If any of the
Company’s health benefits are self-funded as of the date of termination, or if the Company cannot provide the foregoing benefits in a manner that IS exempt from or otherwise compliant with applicable law (including, without limitation,
Section 409A of the Code and Section 2716 of the Public Health Service Act), instead of providing continued health insurance benefits as set forth above, the Company shall instead pay to Employee an amount equal to the monthly plan premium
payment for Employee and his or her eligible dependents who were covered under the Company’s health plans as of the date of termination (calculated by reference to Employee’s premiums as of the date of termination) as currently taxable
compensation in substantially equal monthly installments over the COBRA Coverage Period (or the remaining portion thereof).” 

  
 2 

 6. The first sentence of Section 5(c) of the Agreement is hereby amended to read as
follows: 
 “As a condition to Employee’s receipt of any post-termination benefits pursuant to
Sections 4(g)(iii) or 5(a) above, on or prior to the sixtieth (60th) day following the date of Employee’s termination of employment, Employee shall have executed and delivered a Release (the “Release”) in a form reasonably acceptable to the
Company and any applicable revocation period applicable to such Release shall have expired.” 
 7. This Amendment shall be
and is hereby incorporated in and forms a part of the Agreement. All other terms and provisions of the Agreement shall remain unchanged except as specifically modified herein. The Agreement, as amended by this Amendment, is hereby ratified and
confirmed. 
 [Signature Page Follows] 

  
 3 

 IN WITNESS WHEREOF, the Company and Employee have executed and delivered this Amendment on
the date(s) set forth below. 
  

							
		 		 	CONATUS PHARMACEUTICALS INC.
				
	 Date: July 2, 2013
	 		 	By:	 	/s/ Steven J. Mento
		 		 	Name:	 	Steven J. Mento
		 		 	Title:	 	President and CEO
			
		 		 	EMPLOYEE
			
	 Date: July 2, 2013
	 		 	/s/ Alfred P. Spada, Ph.D.
		 		 	Alfred P. Spada, Ph.D.

 [Signature Page to Amendment to Spada Employment Agreement]EX-10.20

 Exhibit 10.20 
 AMENDMENT TO 
 EMPLOYMENT AGREEMENT 

THIS AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”) is entered into effective as of July 2, 2013, by and
between Gary Burgess, M.B., Ch.B. M.Med. (“Employee”) and Conatus Pharmaceuticals Inc., a Delaware corporation (the “Company”). 
 WHEREAS, the Company and Employee are parties to that certain Employment Agreement dated as of November 1, 2011 (the “Agreement”); and 

WHEREAS, the Company and Employee desire to amend the Agreement on the terms and conditions set forth below. 

NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and adequacy of which is
hereby acknowledged, the Company and Employee hereby amend the Agreement as follows: 
 1. For purposes of the Agreement and this
Amendment, the following terms shall have the following meanings: 
 “Stock Awards. “Stock Awards”
shall mean all stock options, restricted stock and such other awards granted pursuant to the Company’s stock option and equity incentive award plans or agreements and any shares of stock issued upon exercise thereof.” 

“Public Trading Date. “Public Trading Date” shall mean the first date upon which the Company’s common
stock is listed (or approved for listing) upon notice of issuance on any securities exchange or designated (or approved for designation) upon notice of issuance as a national market security on an interdealer quotation system.” 

2. The first sentence of Section 4(a) of the Agreement is hereby amended to read as follows: 

“The Company shall pay to Employee a base salary of USD $288,400.00 per year, payable in accordance with the Company’s usual pay
practices (and in any event no less frequently than monthly).” 
 3. The second sentence of Section 4(b) of the
Agreement is hereby amended to read as follows: 
 “Upon full attainment of the aforementioned criteria, as determined by
the Board or its designee, the Annual Bonus will be equal to thirty-five percent (35%) of Employee’s then-current base salary actually paid for such fiscal year.” 

 4. The Agreement is hereby amended to include Section 4(g), which reads as follows:

 “(g) Acceleration of Vesting of Stock Awards. 

(i) With respect to Stock Awards granted to Employee on or after the Public Trading Date, (A) the vesting
and/or exercisability of fifty percent (50%) of the then-unvested and outstanding portion of such Stock Awards shall be automatically accelerated on the date of a Change of Control, and (B) the remaining fifty percent (50%) of the
then-unvested and outstanding portion of such Stock Awards shall vest and/or become exercisable on the first to occur of (1) the first anniversary of the Change of Control or (2) the date of Employee’s termination of employment by the
Company without Cause or by Employee for Good Reason. 
 (ii) With respect to Stock Awards granted to
Employee on or after the Public Trading Date, subject to Section 5(c), if Employee’s employment is terminated by the Company without Cause or by Employee for Good Reason, the vesting and/or exercisability of each of Employee’s
outstanding Stock Awards shall be automatically accelerated on the date of termination as to the number of Stock Awards that would vest over the Severance Period (as defined below) had Employee remained continuously employed by the Company during
such period. 
 (iii) The foregoing provisions are hereby deemed to be a part of each Stock Award and to
supersede any less favorable provision in any agreement or plan regarding such Stock Award.” 
 5. The first sentence of
Section 5(c) of the Agreement is hereby amended to read as follows: 
 “As a condition to
Employee’s receipt of any post-termination benefits pursuant to Sections 4(g)(ii) and 5(a) above, on or prior to the sixtieth (60th) day following the date of Employee’s termination of employment, Employee shall have executed and delivered
a Release (the “Release”) in a form reasonably acceptable to the Company and any applicable revocation period applicable to such Release shall have expired.” 

6. This Amendment shall be and is hereby incorporated in and forms a part of the Agreement. All other terms and provisions of the
Agreement shall remain unchanged except as specifically modified herein. The Agreement, as amended by this Amendment, is hereby ratified and confirmed. 
 [Signature Page Follows] 

  
 2 

 IN WITNESS WHEREOF, the Company and Employee have executed and delivered this Amendment on
the date(s) set forth below. 
  

							
		 		 	CONATUS PHARMACEUTICALS INC.
				
	Date: July 2, 2013	 		 	By:	 	 /s/ Steven J. Mento

		 		 	Name:	 	Steven J. Mento
		 		 	Title:	 	President and CEO
			
		 		 	EMPLOYEE
			
	Date: July 2, 2013	 		 	 /s/ Gary Burgess

		 		 	Gary Burgess, M.B., Ch.B. M.Med.

 [Signature Page to Amendment to Burgess Employment Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00219-of-00352.parquet"}]]